FDA panel split on Avandia decision



WASHINGTON (CNN) -- A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending changes in how it's prescribed.

Twelve of the committee's 33 members voted to pull Avandia off the market altogether, while only three supported leaving it on the market with its current labeling. Seven wanted to add stiffer language to the current label, and 10 wanted both stiffer language and restrictions on its use.

The vote came on the second day of hearings into the safety of the drug, which studies since 2007 have linked to an increased risk of heart failure. One member abstained, and several said their votes easily could have gone another way.

"I think the evidence of potential harm is stronger now than it was in 2007," said Dr. Peter Savage, the director of the National Institutes of Health's epidemiology division, who voted for stronger warnings and restrictions. "I think if the drug is to remain on the market, we need to consider whether there would be some specific indications in which it would be reserved for use. It seems to me that simply putting a warning, a black-box warning, in the labeling is probably not sufficient to really protect patients."

Avandia manufacturer GlaxoSmithKline (GSK) has insisted on the safety of the medication, which is used to control blood sugar levels in diabetics. But a company-sponsored study that Glaxo said showed there was no higher risk of heart problems came under heavy fire from FDA researchers during proceedings Tuesday and Wednesday.

Before the votes, Chuck Keyserling, who suffers from type 2 diabetes, told the panel he has been taking Avandia for 10 years and can't take an alternative drug because of his physical limits on exercise.

"In making this plea to keep Avandia on the market, I believe I am pleading for my life," Keyserling said. For people in his position, "a negative position on Avandia may be a death sentence."

In two preliminary votes, the advisory panel found that Avandia has an increased risk of heart problems compared with other drugs -- but it made the same determination in 2007 without voting to pull the drug, recommending stronger warnings instead. The committee would not conclude the drug poses an increased risk of death, with most calling the data before them insufficient.

"Until we have a longer-term follow-up we just can't say much about mortality," said committee member Dale Hammerschmidt, a University of Minnesota medical professor.

A strongly worded FDA report last week called Glaxo's RECORD study, which the company cites as evidence of the drug's safety, "inappropriate and biased." It accused Glaxo of repeatedly submitting sloppy data and failing to follow up on reports of problems among patients, including deaths.

And Dr. David Graham, the author of a June study that also found higher risk of heart problems among Avandia users, said the RECORD study would have been dismissed as "garbage" if it had been used to seek the drug's original approval.

But Dr. Murray Stewart, Glaxo's vice president for clinical development, said Tuesday that the company's studies "provide the most robust and reliable data" to assess Avandia's safety -- and those studies have found "no evidence to suggest" the drug increases the risk of heart problems. Stewart defended the RECORD study again Wednesday.

Glaxo says several trials have shown Avandia is safe, but its usage has fallen sharply since a 2007 study that linked it to an increased risk of heart attacks and other related problems. Published estimates indicate annual sales of Avandia have dropped from about $3 billion in 2006 to about $1 billion.

A Senate committee added to the controversy Tuesday. Its leaders released documents they said show Glaxo "failed to publish studies that found serious health risks associated with Avandia in a timely manner and actively promoted the drug despite the known safety concerns."

The documents, which the Senate Finance Committee provided to the FDA, include studies that date back to 2000, the committee's Democratic chairman and ranking Republican said. But in an e-mail, Glaxo spokeswoman Mary Anne Rhyne told CNN the new documents were "a small subset" of millions of pages the company released in connection with lawsuits over the drugs.

"They include drafts and other documents taken out of context, which therefore are incomplete and misleading," Rhyne said. "The documents do not offer new clinically relevant scientific information, and do not provide the full extent of GSK's studies and evaluation of Avandia." To top of page

Frontline troops push for solar energy
The U.S. Marines are testing renewable energy technologies like solar to reduce costs and casualties associated with fossil fuels. Play
25 Best Places to find rich singles
Looking for Mr. or Ms. Moneybags? Hunt down the perfect mate in these wealthy cities, which are brimming with unattached professionals. More
Fun festivals: Twins to mustard to pirates!
You'll see double in Twinsburg, Ohio, and Ketchup lovers should beware in Middleton, WI. Here's some of the best and strangest town festivals. Play
Index Last Change % Change
Dow 16,805.41 127.51 0.76%
Nasdaq 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
Treasuries 2.27 -0.00 -0.09%
Data as of 2:22pm ET
Company Price Change % Change
Ford Motor Co 13.78 -0.62 -4.31%
Microsoft Corp 46.13 1.11 2.47%
Apple Inc 105.22 0.39 0.37%
Bank of America Corp... 16.72 0.12 0.72%
Yahoo! Inc 43.50 0.90 2.11%
Data as of Oct 24

Sections

New York headlines took a straight forward and direct approach with NYC's Ebola news. More

The midterm elections are around the corner, and the economy remains a top concern. With unemployment down and inflation low, why do people still feel the economy stinks? More

Shares of Facebook recently topped $80. They've more than quadrupled from their post-IPO lows of two years ago. Can Mark Zuckerberg keep the momentum in mobile going? More

Host a furniture market. Here's how small town High Point, N.C. rakes in this much money -- twice a year. More

If you're looking to fly this holiday season, the clock's ticking to get the best prices. More

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.